Targeting collagen XVIII improves the efficiency of ErbB inhibitors in breast cancer models
Authors:
- Raman DevarajanRDRaman Devarajan
- Valerio IzziValerio Izzi
- Hellevi PeltoketoHPHellevi Peltoketo
- Gunilla RaskGRGunilla Rask
- Saila KauppilaSKSaila Kauppila
- Marja-Riitta VäisänenMVMarja-Riitta Väisänen
- Heli RuotsalainenHRHeli Ruotsalainen
- Sanna-Maria KarppinenSKSanna-Maria Karppinen
- Timo VäisänenTVTimo Väisänen
- Inderjeet KaurIKInderjeet Kaur
- Jussi KoivunenJKJussi Koivunen
Open Access
- 15 September 2023
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (18)
Abstract
The tumor extracellular matrix (ECM) critically regulates cancer progression and treatment response. Expression of the basement membrane component collagen XVIII (ColXVIII) is induced in solid tumors, but its involvement in tumorigenesis has remained elusive. We show here that ColXVIII was markedly upregulated in human breast cancer (BC) and was closely associated with a poor prognosis in high-grade BCs. We discovered a role for ColXVIII as a modulator of epidermal growth factor receptor tyrosine kinase (ErbB) signaling and show that it forms a complex with ErbB1 and -2 (also known as EGFR and human epidermal growth factor receptor 2 [HER2]) and α6-integrin to promote cancer cell proliferation in a pathway involving its N-terminal portion and the MAPK/ERK1/2 and PI3K/AKT cascades. Studies using Col18a1 mouse models crossed with the mouse mammary tumor virus–polyoma virus middle T antigen (MMTV-PyMT) mammary carcinogenesis model showed that ColXVIII promoted BC growth and metastasis in a tumor cell–autonomous manner. Moreover, the number of mammary cancer stem cells was significantly reduced in the MMTV-PyMT and human cell models upon ColXVIII inhibition. Finally, ablation of ColXVIII substantially improved the efficacy of ErbB-targeting therapies in both preclinical models. In summary, ColXVIII was found to sustain the stemness properties of BC cells and tumor progression and metastasis through ErbB signaling, suggesting that targeting ColXVIII in the tumor milieu may have important therapeutic potential.Keywords
Funding Information
- Research Council of Finland (308867, 251314, 284065)
- Jane and Aatos Erkko Foundation (Project grant)
- Sigrid Juséliuksen Säätiö (Project grant)
- Cancer Foundation Finland (190147, 170138)
- Västerbotten Läns Landsting (ALF RV-866131, ALF RV-932421)
- Finnish Cultural Foundation (Personal grant to R.D.)
- Research Council of Finland (311934)
This publication has 62 references indexed in Scilit:
- Lack of Collagen XVIII Long Isoforms Affects Kidney Podocytes, whereas the Short Form Is Needed in the Proximal Tubular Basement MembraneJournal of Biological Chemistry, 2011
- Aligned Collagen Is a Prognostic Signature for Survival in Human Breast CarcinomaThe American Journal of Pathology, 2011
- Mammary Gland ECM Remodeling, Stiffness, and Mechanosignaling in Normal Development and Tumor ProgressionCold Spring Harbor Perspectives in Biology, 2010
- The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive ImmunityCancer Cell, 2010
- Disruption of Laminin-Integrin-CD151-Focal Adhesion Kinase Axis Sensitizes Breast Cancer Cells to ErbB2 AntagonistsCancer Research, 2010
- Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin SignalingCell, 2009
- HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironmentBreast Cancer Research and Treatment, 2009
- Generation of a functional mammary gland from a single stem cellNature, 2006
- PIK3CA Mutations Correlate with Hormone Receptors, Node Metastasis, and ERBB2, and Are Mutually Exclusive with PTEN Loss in Human Breast CarcinomaCancer Research, 2005
- Prospective identification of tumorigenic breast cancer cellsProceedings of the National Academy of Sciences, 2003